Navigation Links
Researchers present new findings for novel pancreatic cancer vaccine
Date:5/22/2012

CLEVELAND A novel pancreatic cancer vaccine shows promise in improving survival when added to standard treatment, according to new research out of University Hospitals Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine. The Phase 2 data was presented today (embargoed 11:00 am ET) at the Annual Meeting of the Society for Surgery of the Alimentary Tract, part of Digestive Disease Week in San Diego.

In the plenary session titled "Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study" (Tuesday, May 22, 8:00 a.m. PT Abstract # 028), Jeffrey Hardacre, MD, lead investigator, presented the updated data. The multi-site, nationwide study involved 70 patients with resected pancreatic cancer and suggests improvement in 12-month disease-free and overall survival.

"Pancreatic cancer is a deadly disease with long-term survival less than 5%," says Dr. Hardacre, surgical oncologist with UH Case Medical Center and Associate Professor at Case Western Reserve University School of Medicine. "Better treatments are needed to improve survival and we are encouraged by the promising results of this vaccine therapy."

The vaccine, known as Algenpantucel-L, is unique from other approaches in that it is designed to trigger the patient's own immune system to destroy cancer cells. Algenpantucel-L, developed by NewLink Genetics Corporation, was added to standard adjuvant therapy for patients who have successfully undergone pancreatic surgical resection.

A pivotal, nationwide Phase 3 study of the vaccine, also led in part by Dr. Hardacre, has begun and will involve up to 722 patients.

Cancer of the pancreas is the fourth leading cause of cancer death in the United States, killing more than 35,000 Americans each year. Pancreatic cancer is characteristically aggressive with non-specific initial symptoms, making it difficult to diagnose early. Conventional therapies have little impact on prognosis and disease outcome. Surgical resection of the tumor is currently the only chance for a cure. Without resection, overall median survival is four to six months with an estimated five-year survival rate of 0.4 percent to 5 percent.

"Patients with pancreatic cancer have limited options and there have been few advances for this lethal disease in recent years," says Stan Gerson, MD, Director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center at Case Western Reserve University. "We are proud that Jeff and our cancer center have played such a significant role in investigating this promising new treatment option."


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... ... WEDI , the nation’s leading nonprofit authority on the use of health IT ... U.S. Department of Health and Human Services (HHS), announced today the winners of its ... in Arlington, Va. on Wednesday, December 4. , “The WEDI Board of Directors is ...
(Date:12/4/2019)... ... December 04, 2019 , ... While the holidays are a time for ... said Texas A&M AgriLife Extension Service specialists. , “There are many ... benefit your overall wellness,” said Joyce Cavanagh, AgriLife Extension specialist in family economics, College ...
(Date:12/4/2019)... , ... December 04, 2019 , ... ... study of AZD4041 for treating tobacco use and dependence. The study will investigate ... nervous system (CNS) penetrant antagonist of orexin-1 (hypocretin-1) receptors that is being developed ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... worked with EMD Serono, the North American branch of the healthcare business of ... site is designed to educate and inform patients, caregivers, the public, patient advocacy ...
(Date:12/2/2019)... ... December 02, 2019 , ... The Sterling P1000 ... Sterile Processing Department. The elegant design provides a smooth polycarbonate surface that is ... doors that allow for manual loading that provides high flexibility and uses very ...
Breaking Medicine News(10 mins):
(Date:12/4/2019)... WASHINGTON, Pa. (PRWEB) , ... December 04, 2019 ... ... solutions empower physicians to better manage their COPD patient’s symptoms, joined forces nearly ... Tulsa’s COPD patients immediate access to in-person care at times when the attention ...
(Date:12/2/2019)... ... December 02, 2019 , ... A Better Life Recovery, a ... mental health facility, announced it has named Tim Ryan and Jennifer Gimenez as ... advocacy efforts. , "We are proud to announce that Jennifer and Tim have ...
(Date:12/2/2019)... Calif. (PRWEB) , ... December 02, 2019 , ... ... of business support services to dental groups in the United States, today announced ... the community of Tulare, CA. , Patients will enjoy convenient hours, a ...
Breaking Medicine Technology: